The Pharma Data

JANUARY 13, 2021

CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. 175:1091-1101 (1992) 2 Karpusas, M et al., International Immunol. (11):1583 11):1583 (2004) 6 Karpusas M, et al. Structure. 9(4):321-9. About CD40-Ligand.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 15, 2021

3 HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors including breast, gastric, lung and colorectal cancer. About the Enhertu Clinical Development Program. 2,5 In the U.S., Approximately one in five gastric cancers are HER2 positive.3 Enhertu (6.4

Treatment 52

Treatment Trials Disease Therapies 52

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It Field also covered the capabilities and strategies that enable acceleration of Fc-fusion, Fab fragment and bispecific antibodies through pre-clinical development.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147

Drug Discovery World

FEBRUARY 28, 2023

The half-life of proteins expressed through the mRNA technology is also much longer than those of direct protein delivery, which suggests that it could be more effective as a treatment strategy for rare diseases. Therefore, the risk for off-target insertional mutagenesis is greatly reduced.

Disease 130

Disease Treatment Vaccine DNA 130

Conversations in Drug Development Trends

MAY 30, 2024

Differences in regulatory sentiments and industry sponsors’ subsequent clinical development strategies historically restricted access based on geography.

Treatment 81

Treatment Small Molecule Clinical Trials Therapies 81

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

The Pharma Data

APRIL 8, 2021

Roche will present data from five studies from the EVRYSDI clinical development programme, which was designed to represent a broad spectrum of people living with SMA. The full range of data from Roche’s clinical development programme in neuroscience being presented at 2021 AAN include: Medicine and/or Therapeutic Area.

Clinical Trials 52

Clinical Trials Trials Disease Nurses 52

The Pharma Data

MARCH 20, 2023

As the number of patients treated with gene therapy around the world continues to grow, our goal is that more patients, and even new SMA patient populations, will be able to experience the transformative impact of this treatment,” said Sitra Tauscher-Wisniewski, MD, Vice President Clinical Development & Analytics, Novartis Gene Therapies.

Licensing 40

Licensing Licensing Clinical Trials Therapies 40

The Pharma Data

OCTOBER 28, 2020

In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. Angelman syndrome is not a degenerative disorder, but the loss of the UBE3A protein expression in neurons results in abnormal communications between neurons.

Protein Expression 40

Protein Expression Production Therapies Treatment 40

Drug Discovery World

NOVEMBER 13, 2023

Nageatte Ibrahim, MD, Vice President, Oncology & Global Clinical Development, MSD, on: ‘The new age of immunotherapy: From checkpoint inhibitors to vaccines’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

The Pharma Data

SEPTEMBER 2, 2020

Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved. The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

The Pharma Data

AUGUST 9, 2021

Enhertu is being further assessed in a comprehensive clinical development programme evaluating efficacy and safety across multiple HER2-targetable cancers, including breast, gastric, lung and colorectal cancers. 1 More than two million patients with breast cancer were diagnosed in 2020, resulting in nearly 685,000 deaths globally.

Trials 52

Trials Treatment Clinical Trials Protein Expression 52

The Pharma Data

SEPTEMBER 22, 2020

Trial design and other details are being evaluated and a comprehensive update on the overall Novartis SMA clinical development program will be provided at a future time following further discussions with health authorities. This guidance provides clarity on the path to registration for AVXS-101 IT.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 26, 2020

Based on these promising findings, Transgene intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study as we look to provide a better treatment option for this patient population,” added Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene. Conclusions.

Vaccine 52

Vaccine Virus Trials Treatment 52

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52